This trial randomized advanced, pre-treated, NSCLC patients harbouring KRAS codon 12 or 13 mutations to receive abemaciclib with best supportive care (BSC) or erlotinib with BSC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.